tirzepatide clinical trial SURMOUNT-1 Tirzepatide shows 47% greater weight

This growth is primarily driven by the expanding patient populations for type 2 diabetes, obesity, and cardiovascular disease indications, as well as the approaching patent cliff on Novo Nordisk's core semaglutide IP creating substantial generic API demand

The Brain-Gut Rewiring: Why Your Cravings are Muted You may be familiar with the gut-brain connection, or the signaling that occurs in both directions between the brain and the gastrointestinal tract

Inflammatory markers like C-reactive protein (CRP) decline significantly

Managing GLP-1 Side Effects During Your Period Nausea, constipation, and reduced appetite are common semaglutide side effects that may feel amplified during your menstrual cycle

Outside of trials, that figure might be much higher.